Table 2.
Expression of Runx1 isoforms in EVARDS and ARDS outcome
| ARDS sample | Runx1p66 expression | p66/p52 ratio | ICU length of stay (days | ARDS outcome |
|---|---|---|---|---|
| S2; S4; S5*; S6; S10; S13; S14*; S17; S18; S25; S26, S28; S31; S32; S33; S34; S35*; | Yes | High | 28 | 14 long-term survivors 3 deceased* |
| S11; S12; S15 | Yes | Low (< 0.5) | 51 | All deceased |
| S3; S9; S19; S23; S27; | No | – | 12.4 | All alive (the endogenous lung ability to repair is sufficient for recovery) |
| S7; S8; S20; S22 | No | – | 14.5 | All deceased (the endogenous lung ability to repair not sufficient for recovery and no Runx1p66 expression) |
29 EVARDS preparations and 3 EVCtrl were lysed and subjected to WB analyses with Runx1 Ab. Runx1 immunoreactivity was quantified by densitometry (NIH ImageJ) and used to establish the Runx1p66/p52 ratio. EVARDS samples S5*, S14* and S35* illustrate special situations of three ARDS patients that died despite their high Runx1p66/p52 ratio due to other complications (S5) or removal of life support at family’s request (S14, S35)